Publications by authors named "Andrew Capen"

Claim this Profile
[
[Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering].
Zhao Hai Lu, Tomoko Matsui, Audrey Au, Krithi Bala, Amelie Forest, Andrew Capen

Gan To Kagaku Ryoho· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.
Shripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao, Weihua Shen, Andrew Capen

Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
David S Hong, Kathleen N Moore, Johanna C Bendell, Daniel D Karp, Judy S Wang, Andrew Capen

Clin Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
David A Schaer, Sandaruwan Geeganage, Nelusha Amaladas, Zhao Hai Lu, Erik R Rasmussen, Andrew Capen

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Andrew Capen

Mol Cancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
David A Schaer, Richard P Beckmann, Jack A Dempsey, Lysiane Huber, Amelie Forest, Andrew Capen

Cell Rep· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Bruce W Konicek, Andrew R Capen, Kelly M Credille, Philip J Ebert, Beverly L Falcon

Oncotarget· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Jennifer M Atkinson, Kenneth B Rank, Yi Zeng, Andrew Capen, Vipin Yadav

PLoS One· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting.
Rosamund C Smith, Martin S Cramer, Pamela J Mitchell, Andrew Capen, Lysiane Huber

Mol Cancer Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
Anthony Tolcher, Jonathan Goldman, Amita Patnaik, Kyriakos P Papadopoulos, Paul Westwood, Andrew R Capen

Eur J Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization.
Timothy Meier, Mark Uhlik, Sudhakar Chintharlapalli, Michele Dowless, Robert Van Horn, Andrew Capen

Mol Cancer Ther· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.
Jeremy R Graff, Bruce W Konicek, Thomas M Vincent, Rebecca L Lynch, David Monteith, Andrew Capen

J Clin Invest· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Jeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, Bruce W Konicek, Rebecca L Lynch, Andrew Capen

Cancer Res· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis